Indian API manufacturers in the US FDA Drug Master File system
India is one of the largest sources of active pharmaceutical ingredients for US generic medicines, and the Type II Drug Master File (DMF) is the document that connects an Indian API plant to a US Abbreviated New Drug Application (ANDA). A DMF lets the API maker submit confidential chemistry, manufacturing and controls (CMC) information directly to FDA, so the finished-dose applicant can reference it through a Letter of Authorization without ever seeing the proprietary process.
How the FDA DMF list is organised
FDA publishes its list of DMFs as an Excel workbook and posts a new edition each quarter. The edition posted in October 2026 ("3rd Quarter 2026") is current through DMF 044931 and records each file's number, status, type, submission date, holder name and subject. The list is organised per file, not per company, which is where sourcing teams lose time:
- Holder names vary. The same group can appear as a parent company, a renamed entity, an acquired subsidiary or a holder spelled several ways across decades of submissions.
- Status matters. Files are marked active (A) or inactive (I). An inactive file cannot support a new ANDA reference until it is reactivated.
- Type matters. Type II covers drug substances, intermediates and the material used to make them; Type III (packaging), Type IV (excipients) and Type V (other) are not API supplier files.
- Subjects are free text. The same API can be described with or without salt form, hydrate, polymorph or process qualifiers (for example "crystalline", "amorphous" or "sterile").
Completeness assessment and GDUFA fees
Under the Generic Drug User Fee Amendments (GDUFA), a Type II API DMF holder pays a one-time DMF fee when the file is first referenced by a generic application, after which FDA performs an initial completeness assessment. Files that pass are posted on FDA's separate list of Type II API DMFs available for reference. For a buyer, "has a DMF" and "has a DMF that has passed completeness assessment and is available for reference" are different levels of readiness: the second shortens the path for a new ANDA.
What sourcing teams check before qualifying an Indian supplier
| Check | Why it matters |
|---|---|
| Active Type II DMF for the exact salt and form | The ANDA must reference a file covering the specific drug substance being used. |
| GDUFA fee paid / available for reference | Indicates the file has passed FDA's completeness assessment. |
| Inspection history of the API site | FDA warning letters and import alerts on Indian API plants directly affect supply continuity. |
| Parallel filings (CEP, EDMF, JDMF, KDMF) | Suppliers filed in several markets are easier to use across a global portfolio. |
| Backward integration | Captive key starting materials and intermediates reduce exposure to single-country raw-material risk. |
Where the Indian API base is concentrated
The Indian holders sit in established API hubs such as Hyderabad in Telangana, the Mumbai–Thane belt and MIDC industrial estates of Maharashtra, and the National Capital Region around Noida. Holders range from integrated generic groups with hundreds of US filings to focused mid-size producers whose DMFs cover a few niche molecules. The companies in the sample illustrate this range: MSN Laboratories states it holds more than 570 API US DMFs, Jubilant Pharma cites 65 US DMFs, and specialist producers such as Supriya Lifescience publish individual DMF numbers on product pages.
Using DMF holders for second sourcing
Second-sourcing an API for an approved ANDA requires a prior approval or CBE supplement that references the new supplier's DMF, plus comparative data on impurity profile, particle size and polymorphic form. Teams therefore shortlist holders whose active Type II files cover the same form, then contact them for a Letter of Authorization, the open part of the DMF and site audit reports. Mapping holders to operating companies is what turns the FDA file list into a usable supplier shortlist.